United Kingdom Trial of Radioiodine Intervention for Subclinical Hyperthyroidism

亚临床甲状腺功能亢进（SH）是一种轻度甲状腺过度活跃的状态，通过血液中甲状腺激素的测量来定义。这种病很常见，约有2%的老年人患有此病。就像高胆固醇水平一样，大多数人没有SH的症状，但它与血管疾病的风险增加有关。问题是，我们不知道治疗SH是否值得，就血管疾病发病率和其他问题而言是否有益。我们将开展一项试验，比较放射性碘治疗甲状腺过度活跃与SH患者心脏危险因素的标准治疗。我们将在治疗后对SH患者进行5年的随访，以了解这是否能改善血管疾病和其他问题的发生率。这项试验将成为第一个针对这种疾病治疗的随机研究，并将为英国每年约20万老年人的医疗决策提供信息。

Subclinical hyperthyroidism (SH) is a state of mild thyroid gland overactivity, defined by measurement of thyroid hormones in the blood. It is quite common, affecting about 2% of elderly people. Rather like high blood cholesterol levels, most people have no symptoms of SH, but it is associated with an increased risk of vascular disease. The problem is that we don`t know whether treating SH is worthwhile, in terms of benefit to vascular disease rates and other problems.We will carry out a trial comparing radioiodine treatment of the thyroid gland overactivity to standard therapy for cardiac risk factors in patients with SH. We will follow people with SH for 5 years after the treatment to find out whether this improves the rate of vascular diseases and other problems. This trial will form the first randomised study of treatment for this condition and will inform healthcare decision making for about 200,000 elderly people each year in the UK.